NWBO "cash rich"?? That is rich. Can only get funding from vulture funds, the creditors of LAST resort.
The trial has so many warts in it the regulators will have a lot of reservations about it.
Toss out the original primary endpoint, replace protocol, comparator, endpoints and SAP without approval (as confirmed by NWBO SEC filings). Confounded naive OS data, post hoc data dredged rGBM data that was never part of the trial protocol to begin with. Have never seen a biotech trial so manipulated. Regulators won't know what is real out of this dataset.
Investor community knows it as the shareprice had NO positive movement with the TLD presentation. If it was so compelling, there would have been significant positive share movement but instead -- Nada.
Market Data 
Markets 
AI
